Index

Policy Statement Number 5 March 1995 Numerous studies have shown that dose is one of the most important aspects of methadone treatment and that patients who are given an adequate dose, know their dose and have some influence regarding their dose do better in treatment and remain in treatment (Ball and Ross, 1994; Caplehorn and…

DOJ publishes guidance on Opioid Use Disorder and the Americans with Disabilities Act April 15, 2022 “The opioid crisis poses an extraordinary challenge to communities throughout our country. The Department of Justice (the Department) has responded with a comprehensive approach prioritizing prevention, enforcement, and treatment. This includes enforcing the Americans with Disabilities Act (Ada), which…

The Coalition for Methadone Choice is attempting to prevent Mayor Giuliani from ‘detoxing’ more than 2000 patients and threatening treatment for thousands more. We are looking for:                 Methadone maintenance patients to participate in public education and/or lobbying.                 Patients at city-run programs to join in legal efforts to save their treatment.                 Anyone who…

Chair: Dr. P. Kishore, MD, MPH, CMA (Boston NAMA) Committee Members Paul Bowman, CMA  Cheri Jarvis, CMA  The HCV Committee was created to empower methadone patients through education and advocacy and to provide support for those that do test positive for Hepatitis C. What Is Hepatitis C? Hepatitis is an inflammation of the liver. Although…

The next few years will be important and exciting for methadone maintenance treatment. On May 17, 2001 the oversight of methadone was officially removed from the FDA and handed over to the Center for Substance Abuse Treatment. We are currently in a3-year transition period during which CSAT is slowly setting policy which includes accreditation of…